|
An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Amgen; Bristol-Myers Squibb; MSD; Novartis; Novartis; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
Honoraria - Amgen; Novartis |
Consulting or Advisory Role - Amgen; Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Philogen; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Philogen; Roche |
Research Funding - Bristol-Myers Squibb; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche |
Speakers' Bureau - Bristol-Myers Squibb |